Heart patients may get kidney shield from diabetes pills
NCT ID NCT07231939
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether SGLT2 inhibitors (drugs like empagliflozin and dapagliflozin, typically used for diabetes) can prevent acute kidney injury caused by contrast dye used in heart X-rays and stent procedures. Researchers will review records of 4,000 patients who had these heart procedures between 2020 and 2025, comparing those who were taking an SGLT2 inhibitor with those who were not. The goal is to see if the drug reduces the chance of kidney damage within 72 hours after the procedure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SGLT2 inhibitors (empagliflozin or dapagliflozin)
- What this could lead to
- If successful, this could show that taking an SGLT2 inhibitor before heart procedures reduces the risk of kidney damage from contrast dye.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be less reliable. The benefit may be small or not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Collegium Medicum w Bydgoszczy
RECRUITINGBydgoszcz, 85-094, Poland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which emergency dialysis saves more lives? a new study investigates
- Software-Guided heart procedures: a new standard for coronary care?
- Heart patients may stay active longer with coach calls and group support
- Sitting less could be a lifeline for frail hearts – a new trial tests a simple program
- Can balloon timing make or break heart artery success?
- Can we predict which heart aneurysms will grow?